iBio Appoints Thomas D'Alonzo CEO, Sets Salary

TL;DR

iBio names D'Alonzo permanent CEO, $450k salary, effective July 2nd.

AI Summary

On July 2, 2024, iBio, Inc. announced the appointment of Thomas L. D'Alonzo as Chief Executive Officer and a member of the Board of Directors. D'Alonzo, previously the interim CEO, will receive an annual base salary of $450,000 and is eligible for a performance-based bonus. The company also reported on amendments to its Code of Ethics.

Why It Matters

The appointment of a permanent CEO signals a new phase of leadership and strategic direction for iBio, potentially impacting its future development and market performance.

Risk Assessment

Risk Level: medium — Leadership changes and executive compensation can indicate internal shifts and financial strategies that may carry inherent risks for the company's future operations.

Key Numbers

• $450,000 — CEO Annual Salary (Represents the base compensation for the newly appointed CEO, Thomas L. D'Alonzo.)

Key Players & Entities

• iBio, Inc. (company) — Registrant
• Thomas L. D'Alonzo (person) — Appointed CEO and Board Member
• $450,000 (dollar_amount) — Annual base salary for CEO
• July 2, 2024 (date) — Effective date of appointment

FAQ

Key Financial Figures

• $0.001 — ge on which registered Common Stock , $0.001 par value per share IBIO NYSE Americ

Filing Documents

• ibio-20240702x8k.htm (8-K) — 44KB
• ibio-20240702xex10d1.htm (EX-10.1) — 78KB
• ibio-20240702xex10d2.htm (EX-10.2) — 76KB
• ibio-20240702xex10d3.htm (EX-10.3) — 84KB
• ibio-20240702xex10d4.htm (EX-10.4) — 102KB
• ibio-20240702xex10d5.htm (EX-10.5) — 64KB
• ibio-20240702xex10d6.htm (EX-10.6) — 95KB
• ibio-20240702xex10d7.htm (EX-10.7) — 97KB
• ibio-20240702xex14d1.htm (EX-14.1) — 44KB
• 0001420720-24-000029.txt ( ) — 927KB
• ibio-20240702.xsd (EX-101.SCH) — 4KB
• ibio-20240702_def.xml (EX-101.DEF) — 4KB
• ibio-20240702_lab.xml (EX-101.LAB) — 14KB
• ibio-20240702_pre.xml (EX-101.PRE) — 10KB
• ibio-20240702x8k_htm.xml (XML) — 5KB

05 Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics

Item 5.05 Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics. On July 2, 2024, the Company approved and adopted an updated Code of Business Conduct and Ethics (the "Code"), which applies to all directors, officers and employees of the Company. The Code supersedes the existing Code of Business Conduct and Ethics adopted by the Board. The Code has been updated to modernize its language and structure, promote mitigation of risk with Company personnel, and better reflect changes in the Company's day-to-day operations and work environment. The foregoing description of the Code does not purport to be complete and is qualified in its entirety by reference to the full text of the Code, attached hereto as Exhibit 14.1 and incorporated herein by reference.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 Form of Non-Qualified Stock Option Agreement for initial grants for non-employee directors under the iBio Omnibus Incentive Plan 10.2 Form of Non- Qualified Stock Option Agreement for non-employee consultants under the iBio Omnibus Incentive Plan 10.3 Form of Non-Qualified Stock Option Agreement for annual grants for non-employee directors under the iBio Omnibus Incentive Plan 10.4 Form of Non-Qualified Stock Option Agreement for employees under the iBio Omnibus Incentive Plan 10.5 Form of Restricted Stock Unit Award Agreement for employees under the iBio Omnibus Incentive Plan 10.6 Form of Incentive Stock Option Agreement for employees under the iBio Omnibus Incentive Plan 10.7 Form of Incentive Stock Option Agreement for officers under the iBio Omnibus Incentive Plan 14.1 Code of Business Conduct and Ethics 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document) -2-

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IBIO, INC. Date: July 9, 2024 By: /s/ Marc Banjak Name: Marc Banjak Title: General Counsel and Corporate Secretary -3-